Submissions supported by Phase 3 study in which upadacitinib (RINVOQ®) demonstrated significant improvements in signs and symptoms as well as physical function and disease activity versus placebo
- No new safety risks were observed compared to the known safety profile of upadacitinib
- AbbVie has also submitted results from two studies of upadacitinib in adult patients with ankylosing spondylitis (AS) to request label enhancements in the European Union (EU)
- RINVOQ is approved for use in active psoriatic arthritis (PsA), moderate to severe active rheumatoid arthritis (RA), moderate to severe atopic dermatitis (AD) and active AS in the EU, and for PsA and RA in the US
https://finance.yahoo.com/news/abbvie-submits-applications-upadacitinib-rinvoq-140000364.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.